Treatment Patterns in US Patients Receiving First-Line and Second-Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma in the Real World.

King, Gentry; Ittershagen, Stacie; He, Luyang; Shen, Ying; Li, Frank; Villacorta, Reginald

King, Gentry; Ittershagen, Stacie; He, Luyang; Shen, Ying; Li, Frank; Villacorta, Reginald.

Afiliación

King G; Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, WA, USA.
Ittershagen S; Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ, 07936-1080, USA.
He L; KMK Consulting Inc., Morristown, NJ, USA.
Shen Y; KMK Consulting Inc., Morristown, NJ, USA.
Li F; Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ, 07936-1080, USA.
Villacorta R; Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ, 07936-1080, USA. reginald.villacorta@novartis.com.

Adv Ther ; 39(12): 5433-5452, 2022 12.

Article en En | MEDLINE | ID: mdl-36197644

Asunto(s)

Adenocarcinoma; Neoplasias Pancreáticas; Humanos; Neoplasias Pancreáticas/patología; Protocolos de Quimioterapia Combinada Antineoplásica; Estudios Retrospectivos; Adenocarcinoma/tratamiento farmacológico; Albúminas; Paclitaxel; Neoplasias Pancreáticas

Palabras clave

Locally advanced; Metastatic; Overall survival; Pancreatic ductal adenocarcinoma; Real-world outcomes; Treatment duration; Treatment patterns; Treatment switching

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 Problema de salud: 1_sistemas_informacao_saude Asunto principal: Neoplasias Pancreáticas / Adenocarcinoma Tipo de estudio: Guideline / Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Adv Ther Asunto de la revista: TERAPEUTICA Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google